



28 October 2021

The Manager  
Company Announcements Office  
Australian Securities Exchange Limited  
20 Bridge Street  
Sydney NSW 2000

**cyclo**medica  
**techneg**as  
**ultra**lute

Cyclopharm Ltd  
ABN 74 116 931 250  
Unit 4, 1 The Crescent  
Kingsgrove NSW 2208 Australia  
T 61 2 9541 0411  
F 61 2 9543 0960  
[www.cyclopharm.com.au](http://www.cyclopharm.com.au)

## **JOBKEEPER PAYMENTS NOTICE**

Cyclopharm Limited (CYC) provides the appended Jobkeeper payments notice in accordance with subsection 323DB(1) of the Corporations Act 2001.

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

### **For more information, please contact:**

Mr James McBrayer  
Managing Director, CEO and Company Secretary  
Cyclopharm Limited  
T: +61 (02) 9541 0411

### **Cyclopharm Limited**

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas® used in functional lung ventilation imaging.

### **Technegas®**

The Technegas® technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas®, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

# Jobkeeper Payments Notification

*A notice for release to the market under subsection 323DB(1) of the Corporations Act 2001-  
jobkeeper payments disclosure by listed entity.*

Date of this notice

10/28/2021

---

## Listed entity details

Australian Business Number (ABN)

74116931250

ASX/NSX/SSX issuer code

CYC

Name of the listed entity

Cyclopharm Limited

---

## Jobkeeper payments

This notice relates to the financial years ended 12/31/2020 (FY 1) and 12/31/2021 (FY 2).

**The number of individuals for whom the listed entity or a subsidiary of the listed entity received a jobkeeper payment for a jobkeeper fortnight that ended in the financial year** (within the meaning of the Coronavirus Economic Response Package (Payments and Benefits) Rules 2020).

FY 1: 27

FY 2: 0

**The sum of all jobkeeper payments the listed entity, and each subsidiary of the listed entity, received in a jobkeeper fortnight that ended in the financial year.**

FY 1: \$391,500

FY 2: \$0

**Has the listed entity or a subsidiary of the listed entity, made one or more voluntary payments (whether or not in the financial year) to the Commonwealth by way of a repayment of jobkeeper payments received by the listed entity or a subsidiary of the listed in the financial year?**

NO

**If the listed entity or a subsidiary of the listed entity has made such a voluntary payment or payments -the sum of those payments:**

FY 1:\$0

FY 2:\$0